We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Otsuka Holdings Co Limited (PK) | USOTC:OTSKY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.11 | 0.52% | 21.16 | 21.13 | 21.69 | 21.72 | 20.40 | 20.40 | 44,489 | 21:00:03 |
WASHINGTON--The U.S. Supreme Court on Monday refused to consider a generic drug maker's challenge to Otsuka Pharmaceutical Co.'s U.S. patent for the blockbuster antipsychotic drug Abilify.
Two lower courts ruled the patent was valid, rejecting challenges by would-be generic competitors, including Apotex Inc.
Apotex sought to renew its legal arguments at the Supreme Court, but in a short written order, the justices declined to review the case.
Abilify is used to treat schizophrenia and other disorders. Otsuka said in a court brief that Abilify generates annual sales exceeding $5 billion, making it the fourth largest-selling drug in the U.S.
The drug maker's patent expires in 2015.
Bristol-Myers Squibb Co. (BMY) co-markets Abilify with Otsuka in certain countries and shares in its revenue and expenses. Bristol recently eliminated nearly 500 sales and medical jobs because Otsuka is taking over the U.S. promotional responsibilities for the drug.
Write to Brent Kendall at brent.kendall@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Otsuka (PK) Chart |
1 Month Otsuka (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions